Translations:Nicotinamide riboside/15/en
Commercialization
ChromaDex licensed patents in July 2012, and began to develop a process to bring NR to market as TruNiagen. ChromaDex has been in a patent dispute with Elysium Health over the rights to nicotinamide riboside supplements since 2016.